Systemic antivirals for therapy of herpesvirus diseases.
Several chemicals and interferons have been utilized in the prophylaxis and the treatment of a number of human herpesvirus infections. For example, adenine arabinoside as well as acyclovir and human leukocyte interferon appear active against acute varicella zoster and herpes simplex infections in controlled trials. Some of these agents have transient in vivo actions against CMV and EBV as well. Further open trial work with these 2 viruses appears necessary to improve dose regimens or to employ combination therapy or study new derivatives or agents before controlled trials are warranted. Recombinant DNA methodology is currently providing much greater yields of pure interferon for such uses. Recent successes in eradicating chronic hepatitis B virus infection suggest that it is even possible in the future that persistent herpesviruses in the CNS or lymphoreticular systems may be amenable to long-term therapy. As hyperimmune globulin appears to diminish the severity of CMV disease, it is also possible that human monoclonal antibodies may provide a useful approach for immunoprophylaxis as therapy.
D000212:Acyclovir / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000276:immunology; D000998:Antiviral Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D006566:Herpesviridae Infections / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D007165:Immunosuppression Therapy / Q000009:adverse effects; D007372:Interferons / Q000627:therapeutic use; D010746:Phosphonoacetic Acid / Q000627:therapeutic use; D014740:Vidarabine / Q000009:adverse effects / Q000627:therapeutic use
D000911:Antibodies, Monoclonal; D000998:Antiviral Agents; D007372:Interferons; D014740:Vidarabine; D010746:Phosphonoacetic Acid; D000212:Acyclovir